Genovis has been granted a patent for new Streptococcal proteases, termed IgdE, which exhibit IgG degrading cysteine protease activity. The patent includes in vitro methods for cleaving human IgG1, generating Fc and Fab fragments, and detecting IgG using these proteases. GlobalData’s report on Genovis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Genovis, Nanorobotics was a key innovation area identified from patents. Genovis's grant share as of June 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Streptococcal proteases for cleaving human igg1 in vitro
The patent US12006530B2 outlines an in vitro method for cleaving human IgG1 using a purified polypeptide. The method involves contacting human IgG1 with a polypeptide that either has the amino acid sequence of SEQ ID NO: 3, a variant with at least 95% identity to this sequence and exhibiting human IgG1 cysteine protease activity, or a fragment of either. The process includes incubating the polypeptide with a sample containing human IgG1 under conditions that facilitate specific cysteine protease activity. Additionally, the method allows for the identification and isolation of cleavage products, which can be analyzed through techniques such as gel electrophoresis or mass spectrometry.
Furthermore, the method can be utilized to generate Fc and Fab fragments from human IgG1 and to detect the presence of human IgG1 in samples. This detection process involves monitoring for specific cleavage fragments indicative of human IgG1 after contacting the sample with the purified polypeptide. Notably, the purified polypeptide can be a recombinant variant, enhancing its applicability in various research and clinical settings. The claims emphasize the specificity and efficiency of the method, which could have significant implications for therapeutic and diagnostic applications involving human IgG1.
To know more about GlobalData’s detailed insights on Genovis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
